scispace - formally typeset
G

Gregory M. Anstead

Researcher at University of Texas Health Science Center at San Antonio

Publications -  83
Citations -  6333

Gregory M. Anstead is an academic researcher from University of Texas Health Science Center at San Antonio. The author has contributed to research in topics: Indene & Estrogen receptor binding. The author has an hindex of 24, co-authored 80 publications receiving 6107 citations. Previous affiliations of Gregory M. Anstead include University of Kentucky & United States Department of Veterans Affairs.

Papers
More filters
Journal ArticleDOI

Effects of glutamine alone or in combination with zinc and vitamin A on growth, intestinal barrier function, stress and satiety-related hormones in Brazilian shantytown children

TL;DR: Benefits of glutamine alone or in combination with other gut-trophic nutrients in growing children via interactions with leptin are revealed, and glutamine and all combined nutrients improved the intestinal barrier function in these children.
Journal ArticleDOI

Primary esophageal lymphoma: a diagnostic challenge in acquired immunodeficiency syndrome--two case reports and review.

TL;DR: Primary esophageal lymphoma should be considered in the differential diagnosis in a human immunodeficiency virus-seropositive patient presenting with dysphagia, reflecting the poor prognosis associated with this malignancy.
Journal ArticleDOI

Torsionally and hydrophobically modified 2,3-diarylindenes as estrogen receptor ligands.

TL;DR: The effect of the ortho substitution on increasing receptor binding appears to be a combination of increased surface area due to the substituent itself, together with a change in surface area of the ligand that results from the increased torsion of the two aryl rings.
Book ChapterDOI

Treatment of infections caused by resistant Staphylococcus aureus.

TL;DR: Despite the emergence of resistant and multidrug resistant S. aureus, five effective drugs for which little resistance has been observed are in clinical use: vancomycin, quinupristin-dalfopristin, linezolid, tigecycline, and daptomycin.